Legal Representation
Attorney
Andrew D. Price
USPTO Deadlines
Next Deadline
1260 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20230627)
Due Date
June 27, 2029
Grace Period Ends
December 27, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 27, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jun 27, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 11, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 11, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 22, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 8, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 8, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 8, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 6, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 13, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 13, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 13, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 13, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 11, 2022 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Mar 10, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Mar 9, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Mar 4, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 4, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical, therapeutic and medicinal preparations and substances to increase the avidity of antibodies for the treatment of cancer; all the foregoing containing monoclonal antibodies; pharmaceutical compounds for the treatment of cancer, all the foregoing containing monoclonal antibodies
Classification
International Classes
005